Double-blind cross-over study of phosphatidylserine vs. placebo in patients with early dementia of the Alzheimer type.
Quick navigation
Link to full study
http://www.ncbi.nlm.nih.gov/pubmed/1633433
Conclusion of this study
The improvement carried over to the following wash-out and treatment phases. There were no significant improvements in GBS dementia rating scale, psychometric tests or P300-latency. 16-channel EEG mapping findings indicated that the patients initially showed higher power values in all frequency bands (except alpha), when compared to a younger, healthy control group. BC-PS reduced the higher power values compared to placebo, shifting EEG power more towards the normal level.
Supplements analyzed in this study
Health conditions analyzed in this study
Functions related to this study
Body systems related to this study
